Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
EN
Results of in vivo and in vitro experiments have demonstrated the presence of a local renin-angiotensin system (RAS) in the prostate. However, the role of this system in the physiology and pathology of the prostate is still unclear. Recent reports have indicated that RAS is also involved in the regulation of cell proliferation, differentiation, migration as well as angiogenesis, inflammation and apoptosis, which suggests its important role in carcinogenesis. Reorganization of individual elements of the renin-angiotensin system has been reported in both benign prostatic hyperplasia and prostate cancer. These changes concerned the expression of AT1 receptor, angiotensin converting enzyme (ACE) and local concentration of angiotensin II or angiotensinogen. This review focuses on the role of RAS in the induction and progression of prostate cancer as well as on the analysis of potential benefits of RAS modulation in anticancer therapy.
PL
Wyniki badań in vivo oraz in vitro ujawniły obecność lokalnego układu renina-angiotensyna (RAS) w gruczole krokowym, niemniej jednak rola tego układu zarówno w fizjologii jak i patologii stercza nadal nie jest dobrze znana. Najnowsze doniesienia wskazują, że RAS obok swojej klasycznej roli jest zaangażowany w proliferację, różnicowanie i migrację komórek, angiogenezę, procesy zapalne oraz apoptozę, co sugeruje jego istotny udział w procesie kancerogenezy. Reorganizacja poszczególnych elementów RAS została odnotowana zarówno w łagodnym rozroście jak i nowotworach złośliwych gruczołu krokowego. Powyższe zmiany dotyczyły między innymi, poziomu receptora AT1, ekspresji enzymu konwertującego angiotensynę I jak również lokalnego stężenia angiotensyny II i angiotensynogenu. Niniejsza praca ma na celu podsumowanie dotychczasowej wiedzy odnośnie udziału RAS w zapoczątkowaniu i późniejszym rozwoju raka stercza, jak również przeanalizowanie potencjalnych korzyści wynikających z modulacji RAS w kontekście terapii antynowotworowej.
EN
The aim of this study was to evaluate the coexpression of caveolin-1 (CAV-1), angiotensin II type 1 receptor (AT1-R) and forkhead box Ml (FOXM1) in prostate and breast cancer cell lines, in comparison with normal cell lines. CAV-1, AT1-R and FOXM1 expression was determined by reverse transcription-quantitative polymerase chain reaction and western blot analysis in the prostate cancer cell lines PC3, DU145 and LNCaP; prostate normal cell line PNT1A; breast cancer cell lines MCF-7 and MDA-MB-231; and the normal breast cell line 184A1. A correlation between the expression levels of the investigated genes and their metastatic properties was determined by the Spearman's rank test (P<0.05) and Aspin-Welsch t-test, respectively. In prostate cell lines, a significant correlation was noted between CAV-1 and AT1-R expression and between FOXM1 and CAV-1 expression. A correlation between the expression levels of the investigated genes and their metastatic potential was also observed, with relatively high expression of all the investigated genes in the normal prostate cell line PNT1A. In comparison to prostate cancer cell lines, an adverse dependency between CAV-1, AT1-R, FOXM1 expression and metastatic potential was observed in the breast cancer cell lines. Relatively high expression of all tested genes was observed in the normal breast cell line 184A1, which was decreasing respectively with increasing metastatic potential of breast cancer cell lines. The results obtained here indicate that CAV-1, FOXM1 and AT1-R may be potential markers of tumorigenesis in certain types of cancer in vitro.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.